Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions
Résumé
Biological agents (BA) are emerging as potential effectivetreatment for allergic and hypersensitivity disorders (A/H). Fourmain classes of BA are now (May 2020) approved by US Foodand Drug Administration and European Medicines Agency forA/H: anti-IgE (omalizumab),1 anti-IL5 (mepolizumab, reslizu-mab),2 anti-IL4/13 (dupilumab),3 and anti-IL5R (benralizu-mab).4 Hypersensitivity reactions (HSR) due to BA can occurwith different severity degrees, which hamper their use. Newtypes of HSR have been reported with lack of standardized andguided allergy workup
Domaines
AllergologieOrigine | Fichiers produits par l'(les) auteur(s) |
---|